• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Safety and early hints of benefit seen in phase 1b trial of PF-04447943

Sickle cell disease (SCD) patients were safely treated with a phosphodiesterase 9A (PDE9) inhibitor therapy called PF-04447943 with no serious side effects reported and possible evidence of fewer vaso-occlusion pain crises, a Phase 1b clinical trial reports.

Safety and early signs of possible efficacy — including a drop in biomarkers linked to vaso-occlusion — were seen regardless of whether patients given PF-0444794 3 were also taking hydroxyurea.

The study, “PF-04447943, a phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study” was published in the journal, Clinical and Translation Science.

Sickle cell disease, caused by an inherited alteration in a gene that instructs the making of the beta-globin subunit of hemoglobin, the protein responsible for carrying oxygen in the blood, leads to sickle hemoglobin production and sickle-shaped red blood cells.